Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNLSFN)

Drug Name
Olezarsen Drug Info
Indication
Disease Entry ICD 11 Status REF
Familial chylomicronemia syndrome 5C80 Phase 3 [1]
Hypertriglyceridemia 5C80.1 Phase 3 [2]
Cross-matching ID
TTD Drug ID
DMNLSFN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting ApoC-III messenger RNA (APOC3 mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Volanesorsen DM1YEPS Hypertriglyceridemia 5C80.1 Approved [4]
ARO-APOC3 DMABKHH Familial chylomicronemia syndrome 5C80 Phase 3 [5]
ISIS-APOCIII DMX3FN4 Atherosclerosis BD40 Phase 1 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ApoC-III messenger RNA (APOC3 mRNA) TTXOZQ1 APOC3_HUMAN Inhibitor [3]

References

1 ClinicalTrials.gov (NCT05130450) An Open-Label Extension Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS). U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05681351) An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG). U.S.National Institutes of Health.
3 Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022 Apr 6;43(14):1401-1412.
4 Metabolism and Disposition of Volanesorsen, a 2'- O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species. Drug Metab Dispos. 2019 Oct;47(10):1164-1173.
5 ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Curr Atheroscler Rep. 2021 Mar 10;23(5):20.
6 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).